{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:21:31Z","timestamp":1792002091260,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The majority of HBeAg-positive mothers with chronic hepatitis B have high levels of viremia and inactive disease with normal alanine aminotransferase (ALT) during pregnancy. In addition, postpartum disease activation and ALT flare have been reported in the range of 15 \u2212\u200935%. However, the current International Association Guidelines have not provided clear recommendations and a risk-stratified monitoring schedule. Furthermore, data are lacking on the definition of normal ALT in the postpartum period in mothers with chronic hepatitis B. The clinical features and ALT flare patterns in HBeAg-positive mothers versus HBeAg-negative mothers are not fully explored. Thus, we design a cohort study to investigate the aforementioned area and generate data to assist healthcare providers in better managing mothers with hepatitis B. We aim to assess the frequency of postpartum ALT flares and predictors for such events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This study is a single-center and prospective cohort study (n\u2009=\u2009360) that consists of two groups of patients including HBsAg-positive mothers (n\u2009=\u2009120) and healthy mothers without HBV infection (n\u2009=\u2009240). In HBeAg-positive mothers, antiviral therapy during late pregnancy is permitted to prevent Mother-to-child transmission (MTCT) but discontinued at delivery if there is no further indication for the treatment. Mothers are enrolled at the gestational weeks of 12\u201324. After delivery, both mothers and their infants will be followed up until postpartum week 24. Clinical and laboratory data are collected every 4 weeks during the study except there are no follow-up visits at the postpartum weeks 16 and 20. The primary objective is the proportion of patients with postpartum ALT flares. The secondary objectives are independent risk factors during pregnancy for predicting postpartum ALT flares and the normal range of postpartum ALT levels in healthy mothers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The current study focuses on the incidence of postpartum ALT flares in mothers with chronic hepatitis B including subgroup analysis based on HBeAg status. The data will have several clinical implications, such as providing evidence for an appropriate monitoring schedule in CHB mothers after delivery. Further analyses on predictors of such events may assist clinicians in identifying mothers who might develop severe postpartum ALT flares. The data generated from healthy mothers have the potential to identify the patterns of ALT changes during pregnancy and postpartum, so we can gain a better understanding of the normal range of ALT in this subpopulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration Number at the Chinese Clinical Trial Registry<\/jats:title>\n                    <jats:p>ChiCTR2200061130.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-023-02966-2","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T08:01:34Z","timestamp":1699689694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incidence and predictors of elevated postpartum alanine aminotransferase in chronic hepatitis B mothers: a prospective study protocol"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0173-3276","authenticated-orcid":false,"given":"Shi","family":"OuYang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-9453","authenticated-orcid":false,"given":"Ziren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4399-4757","authenticated-orcid":false,"given":"Tingting","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5789-9403","authenticated-orcid":false,"given":"Yawen","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8815-8096","authenticated-orcid":false,"given":"Junchao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7746-8555","authenticated-orcid":false,"given":"Zhirong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-6688","authenticated-orcid":false,"given":"Calvin Q.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"2966_CR1","unstructured":"WHO. Global hepatitis report. Geneva: World Health Organization. 2017"},{"key":"2966_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12879-016-1734-5","volume":"16","author":"G Jourdain","year":"2016","unstructured":"Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, Salvadori N, Decker L, Traisathit P, Sirirungsi W, et al. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis. 2016;16:393.","journal-title":"BMC Infect Dis"},{"key":"2966_CR3","first-page":"496","volume":"16","author":"F Wei Zheng","year":"2010","unstructured":"Wei Zheng F, Cui X, Gong. Analysis of the prevalence of HBsAg and e antigen in women of childbearing age in China. Chin J Vaccines Immun. 2010;16:496\u20139.","journal-title":"Chin J Vaccines Immun"},{"issue":"2","key":"2966_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L: EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"4","key":"2966_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"01","key":"2966_CR6","first-page":"9","volume":"23","author":"Z Guiqiang Wang","year":"2020","unstructured":"Guiqiang Wang Z, Duan F, Wang, et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition). J Practical Liver Disease. 2020;23(01):9\u201332.","journal-title":"J Practical Liver Disease"},{"issue":"5","key":"2966_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41395-018-0010-2","volume":"113","author":"W Yi","year":"2018","unstructured":"Yi W, Pan CQ, Li MH, Wan G, Lv YW, Liu M, Hu YH, Zhang ZY, Xie Y. The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B. Am J Gastroenterol. 2018;113(5):686\u201393.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"2966_CR8","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1136\/gutjnl-2014-308211","volume":"64","author":"M Giles","year":"2015","unstructured":"Giles M, Visvanathan K, Lewin S, Bowden S, Locarnini S, Spelman T, Sasadeusz J. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut. 2015;64(11):1810\u20135.","journal-title":"Gut"},{"issue":"24","key":"2966_CR9","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","volume":"374","author":"CQ Pan","year":"2016","unstructured":"Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, Zhang H, Zou H, Zhu B, Zhao W, et al. Tenofovir to prevent Hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"2966_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/MCG.0000000000000664","volume":"51","author":"CQ Pan","year":"2017","unstructured":"Pan CQ, Dai E, Bhamidimarri KR, Zeng Z, Yin P. Clinical features of Chronic Hepatitis B in Treatment-naive asian patients with positive HBeAg and coexisting precore and\/or basal core promoter mutations. J Clin Gastroenterol. 2017;51(3):261\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"2966_CR11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/jvh.13315","volume":"27","author":"MR Li","year":"2020","unstructured":"Li MR, Xu ZG, Lu JH, Zheng HW, Ye LH, Liu YY, Liu ZQ, Zhang HC, Huang Y, Dai EH, et al. Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and\/or precore mutations. J Viral Hepat. 2020;27(10):1044\u201351.","journal-title":"J Viral Hepat"},{"issue":"2","key":"2966_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.dld.2019.06.021","volume":"52","author":"Y Luo","year":"2020","unstructured":"Luo Y, Pan M, Ning M, Chenyu X, Liu L, Chen L, Chen T, Biyun X, Yali H, Zhou YH. High mutation prevalence of precore and basal core promoter in pregnant women who underwent spontaneous HBeAg seroconversion within one year postpartum. Dig Liver Dis. 2020;52(2):199\u2013204.","journal-title":"Dig Liver Dis"},{"issue":"40","key":"2966_CR13","doi-asserted-by":"publisher","first-page":"e30408","DOI":"10.1097\/MD.0000000000030408","volume":"101","author":"T Kushner","year":"2022","unstructured":"Kushner T, Park C, Masand D, Rosenbluth E, Carroll C, Grace M, Rodriguez-Rivas C, De La Cruz H, Overbey J, Sperling R. Prevalence of elevated alanine aminotransferase (ALT) in pregnancy: a cross-sectional labor and delivery-based assessment. Medicine. 2022;101(40):e30408.","journal-title":"Medicine"},{"issue":"26","key":"2966_CR14","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.3346\/jkms.2020.35.e198","volume":"35","author":"SM Lee","year":"2020","unstructured":"Lee SM, Park JS, Han YJ, Kim W, Bang SH, Kim BJ, Park CW, Kim MY. Elevated alanine aminotransferase in early pregnancy and subsequent development of gestational diabetes and Preeclampsia. J Korean Med Sci. 2020;35(26):e198.","journal-title":"J Korean Med Sci"},{"issue":"10","key":"2966_CR15","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/MCG.0000000000000877","volume":"52","author":"J Liu","year":"2018","unstructured":"Liu J, Wang J, Qi C, Cao F, Tian Z, Guo D, Yan T, Li Q, Yang S, Fu J, et al. Baseline Hepatitis B Virus Titer predicts initial postpartum hepatic flare: a Multicenter prospective study. J Clin Gastroenterol. 2018;52(10):902\u20137.","journal-title":"J Clin Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02966-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02966-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02966-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T08:02:17Z","timestamp":1699689737000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02966-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2966"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02966-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2501080\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research project will be conducted in compliance with the International Conference Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. All participants in the study will require to sign the written informed consent before enrollment. The Ethics Committee of the Fifth Affiliated Hospital of Guangzhou Medical University approved the study on May 23, 2022 (approval number: GYWY-Y2022-56).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. We will not publish participants\u2019 identification information or images in online open-access publications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}